Clinical Report: Can Oral Gildeuretinol Slow Advanced Macular Degeneration?
Overview
Oral gildeuretinol acetate did not significantly slow geographic atrophy progression compared to placebo in patients with age-related macular degeneration.
Background
Geographic atrophy secondary to age-related macular degeneration is a leading cause of vision loss in older adults. Effective treatments are needed to slow disease progression.
Data Highlights
No statistically significant difference in geographic atrophy lesion growth was observed between gildeuretinol and placebo groups.
Key Findings
- The primary endpoint of reduced geographic atrophy lesion growth was not met.
- Gildeuretinol showed a 13% reduction in lesion growth compared to placebo, which was not statistically significant.
- In a sensitivity analysis, lesion growth reduction was 15% with gildeuretinol.
- Patients on gildeuretinol experienced less decline in low-luminance visual acuity compared to placebo.
- Quality of life, as measured by the VFQ-25, improved in the gildeuretinol group.
- Safety profiles were similar between treatment groups, with no new safety signals identified.
Clinical Implications
The findings indicate that gildeuretinol did not meet its primary efficacy endpoint.
Conclusion
The study indicates that oral gildeuretinol acetate did not achieve its primary endpoint.
Related Resources & Content
- Gildeuretinol Acetate vs Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration: The SAGA Randomized Clinical Trial - PubMed
- retinal physician — Oral Gildeuretinol Slows Stargardt Progression
- Retinal Physician — Oral Drug Slows GA Progression in Study
- Retinal Physician — Supplements Slow Geographic Atrophy Progression
- Ophthalmology Management — Study Finds Supplements May Not Slow GA Growth
- Oral Gildeuretinol Slows Stargardt Progression
- Oral Drug Slows GA Progression in Study
- Supplements Slow Geographic Atrophy Progression
- Age-Related Macular Degeneration Preferred Practice Pattern® - Ophthalmology
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE - ScienceDirect
- Gildeuretinol Acetate vs Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration: The SAGA Randomized Clinical Trial - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
